Robert L Ferris
Overview
Explore the profile of Robert L Ferris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
443
Citations
20235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li H, Zandberg D, Kulkarni A, Chiosea S, Santos P, Isett B, et al.
Cancer Cell
. 2025 Mar;
PMID: 40086437
We leverage a clinical trial (NCT04080804) that compared neoadjuvant anti-PD-1, anti-PD-1+CTLA-4, and anti-PD-1+LAG-3 therapies in head and neck squamous cell carcinoma patients. Combination therapies promote higher pathologic response rates versus...
2.
McCoon P, Wang Y, Lai Z, Zhang Q, Li W, Wildsmith S, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40080442
Purpose: Understanding the mutational landscape of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is important in identifying biomarkers to determine which patients may benefit from immune checkpoint inhibitors...
3.
Ruffin A, Casey A, Kunning S, MacFawn I, Liu Z, Arora C, et al.
Sci Transl Med
. 2025 Feb;
17(786):eadh1315.
PMID: 39970232
Many patients with recurrent and metastatic cancer fail to produce a durable response to immunotherapy, highlighting the need for additional therapeutic targets to improve the immune landscape in tumors. Recent...
4.
Bhatia S, Topalian S, Sharfman W, Meyer T, Steven N, Lao C, et al.
J Clin Oncol
. 2025 Jan;
43(9):1137-1147.
PMID: 39889250
Purpose: Approximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune checkpoint inhibition (ICI) with...
5.
Wang J, Li H, Kulkarni A, Anderson J, Upadhyay P, Onyekachi O, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39773563
Background: The transmembrane protein T-cell immunoglobulin and mucin-domain containing molecule 3 (TIM-3) is an immune checkpoint receptor that is expressed by a variety of leukocyte subsets, particularly in the tumor...
6.
Patel M, Burtness B, Ferris R, Saba N
J Natl Cancer Inst
. 2024 Dec;
117(3):388-390.
PMID: 39699215
No abstract available.
7.
Contrera K, Spector M, Pantanowitz L, Abukhiran I, Vujanovic L, Whiteside T, et al.
JCO Precis Oncol
. 2024 Nov;
8():e2400183.
PMID: 39565979
CD8 tumor-infiltrating lymphocytes (TILs) are increasingly used in oncology as a prognostic and predictive tool to guide patient management. This review summarizes current literature on CD8 TILs in head and...
8.
McIlvried L, Martel Matos A, Yuan M, Atherton M, Obuekwe F, Nilsen M, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39551606
Background: Immune checkpoint inhibitors (ICIs) are becoming the standard of care for recurrent and metastatic cancer. Opioids, the primary treatment for cancer-related pain, are immunosuppressive raising concerns about their potential...
9.
Daniels K, Awad D, Liu S, Mocharnuk J, Kubik M, Kim S, et al.
Oral Oncol
. 2024 Sep;
159:107031.
PMID: 39305828
Objectives: Transoral robotic surgery (TORS) for the treatment for oropharyngeal squamous cell carcinoma (SCC) carries a risk of post-operative hemorrhage. Increased time from surgery to completion of adjuvant therapy has...
10.
Zandberg D, Hong C, Swartz A, Hsieh R, Anderson J, Ferris R, et al.
BJC Rep
. 2024 Sep;
2(1):70.
PMID: 39281316
Background: Biomarkers that effectively predict response to anti-PD-1 mAb therapy in cancer patients are an unmet need. We evaluated the utility of small extracellular vesicles (sEV) as biomarkers of response...